2. Academic Validation
  3. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria

  • Haematologica. 2022 Jun 1;107(6):1483-1488. doi: 10.3324/haematol.2020.265868.
Jun-Ichi Nishimura 1,  Kiyoshi Ando 2,  Masayoshi Masuko 3,  Hideyoshi Noji 4,  Yoshikazu Ito 5,  Jiri Mayer 6,  Laimonas Griskevicius 7,  Christoph Bucher 8,  Florian Müllershausen 8,  Peter Gergely 8,  Izabela Rozenberg 8,  Anna Schubart 8,  Raghav Chawla 8,  Jean-Michel Rondeau 8,  Michael Roguska 8,  Igor Splawski 8,  Mark T Keating 8,  Leslie Johnson 8,  Rambabu Danekula 8,  Morten Bagger 8,  Yoko Watanabe 8,  Börje Haraldsson 8,  Yuzuru Kanakura 9
Affiliations

Affiliations

  • 1 Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita. [email protected].
  • 2 Department of Hematology and Oncology, Tokai University, Isehara.
  • 3 Department of Hematology, Endocrinology and Metabolism, Niigata University Medical and Dental Hospital, Niigata.
  • 4 Department of Cardiology and Hematology, Fukushima Medical University, Fukushima.
  • 5 Department of Hematology, Tokyo Medical University, Shinjuku-ku, Tokyo.
  • 6 Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital and Faculty of Medicine, Brno, Czech Republic.
  • 7 Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos and Institute of Clinical Medicine, Vilnius University, Vilnius.
  • 8 Novartis Institutes for BioMedical Research, Basel, Switzerland, Cambridge, USA, and Novartis Pharma KK, Toranomon Minato-ku, Tokyo.
  • 9 Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan; Sumitomo Hospital, Osaka.
PMID: 35263983 DOI: 10.3324/haematol.2020.265868
Figures
Products